EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro

British Journal of Pharmacology

Volumn 125, Issue 5, 1998, Pages 953-962

  James, Sharon Y ^a   Mercer, Elizabeth ^a   Brady, Matthew ^a   Binderup, Lise ^b   Colston, Kay W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Leo Pharmaceutical Products ^*  (Denmark)

Author keywords

Apoptosis; Breast cancer; DNA fragmentation; Oncoproteins; Vitamin D analogues

Indexed keywords

CALCITRIOL; CALCIUM ION; DNA FRAGMENT; METHYLNITROSOUREA; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; SEOCALCITOL; VITAMIN D DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CALCIUM BLOOD LEVEL; CELL STRAIN MCF 7; CONTROLLED STUDY; DENSITOMETRY; DNA DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CALCITRIOL; DNA FRAGMENTATION; FEMALE; GENE EXPRESSION; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; TUMOR CELLS, CULTURED; VITAMIN D;

EID: 0031730375     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702103     Document Type: Article

References (55)

1. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcaemia. Endocrinology, 129, 832-837.
2. ARENDS, M.J., MORRIS, R.G. & WYLLIE, A.H. (1990). Apoptosis; the role of the endonuclease. Am. J. Pathol., 136, 593-608.
3. BARGOU, R.C., DANIEL, P.T., MAPARA, M.Y., BOMMERT, K., WAGENER, C., KALLINICH, H.D., ROYER, H.D. & DÖRKEN, B. (1995). Expression of the bcl-2 gene family in normal and malignant breast cancer: low bax-α expression in tumour cells correlates with resistance towards apoptosis. Int. J. Cancer, 60, 854-859.
4. BARGOU, R.C., WAGENER, C., BOMMERT, K., MAPARA, M.Y., DANIEL, P.T., ARNOLD, W., DIETEL, M., GUSKI, H., FELLER, A., ROYER, H.D. & DÖRKEN, B. (1996). Overexpression of the death-promoting bax-α which is down-regulated in breast cancer restores sensitivity to different apoptotic stimuli and reduced growth in SCID mice. J. Clin. Invest., 97, 2651-2659.
5. 3 receptor in breast cancer and relationship to prognosis. Cancer Res., 51, 239-244.
6. BRADFORD, M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein dye binding. Analyt. Biochem., 72, 248-254.
7. BUCKBINDER, L., TALBOTT, R., VELASCO-MIGUEL, S., TAKENAKA, I., FAHA, B., SEIZINGER, B.R. & KLEY, N. (1995). Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature, 377, 646-649.
8. COLSTON, K., CHANDER, S.K., MACKAY, A.G. & COOMBES, R.C. (1992a). Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol., 44, 693-702.
9. COLSTON, K.W., MACKAY, A.G., JAMES, S.Y., BINDERUP, L., CHANDER, S. & COOMBES, R.C. (1992b). EB1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol., 44, 2273-2280.
10. 3 derivatives and breast cancer. In Schering Foundation Workshop, Vol. 14: Workshop on Apoptosis in Hormone Dependent Cancers. ed. Tenniswood, M. & Michna, H. pp. 181-200. Berlin, Springer-Verlag.
11. COLSTON, K.W., PERKS, C.M., XIE, S.P. & HOLLY, J.M.P. (1998). Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. Mol. Cell. Endocrinol., 20, 157-162.
12. COSMAN, D. (1994). A family of ligands for the TNF receptor superfamily. Stem Cells, 12, 440-455.
13. ELLEDGE, R.M., GREEN, S., HOWES, L., CLARK, G.M., BERARDO, M., ALLRED, D.C., PUGH, R., CIOCCA, D., RAVID, P., O'SULLIVAN, J., RIVKIN, S., MARTINO, S. & OSBORNE, C.K. (1997). bcl-2, p53, and response to tamoxifen in oestrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J. Clin. Oncol., 15, 1916-1922.
14. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res., 55, 2822-2830.
15. FLANAGAN, L., ETHIER, S. & WELSH, J. (1997). Vitamin D induced apoptosis on oestrogen independent breast cancer cells and tumours. In Vitamin D; chemistry, biology and clinical applications of the steroid hormone, ed. Norman A.W., Bouillon, R. & Thomasset, M. pp. 459-460. University of California.
16. GOTTLIEB, T.M. & OREN, M. (1996). p53 in growth control and neoplasia. Biochim. Biophys. Acta, 1287, 77-102.
17. 3 prolong survival time of mice inoculated with myeloid leukaemia cells. Proc. Natl. Acad. Sci. U.S.A., 80, 201-206.
18. HORI, M., NOGAMI, T., ITABASHI, M., YOSHIMI, F., ONO, H. & KOIZUMI, S. (1997). Expression of bcl-2 in human breast cancer: correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis. Pathol. Int., 47, 757-762.
19. HUANG, Y., RAY, S., REED, J.C., IBRADO, A.M., TANG, C., NAWABI, A. & BHALLA, K. (1997). Oestrogen increases intracellular pBcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer cells. Breast Cancer Res. Treat., 42, 73-81.
20. JACOBSON, M.D. & EVAN, G.I. (1994). Apoptosis: breaking the ICE. Curr. Biol., 4, 337-340.
21. JAMES, S.Y., MACKAY, A.G., BINDERUP, L. & COLSTON, K.W. (1994). Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J. Endocrinol., 141, 555-563.
22. JAMES, S.Y., MACKAY, A.G. & COLSTON, K.W. (1995). Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J. Molec. Endocrinol., 14, 391-394.
23. 3 and its analogues on induction of apoptosis in breast cancer cells. J. Steroid Biochem. Molec. Biol., 58, 395-401.
24. 3 in vitro and in vivo effects on human preleukaemic and leukaemic cells. Cancer Treat. Rep., 69, 1399-1407.
25. KYPRIANOU, N., ENGLISH, H., DAVIDSON, N. & ISAACS, J. (1991). Programmed cell death during regression of the MCF-7 human breast cancer following endocrine ablation. Cancer Res., 51, 162-166.
26. KRAJEWSKI, S., BLOMQVIST, C., FRANSSILA, K., KRAJEWSKA, M., WASENIUS, V.-M., NISKANEN, E., NORDING, S. & REED, J.C. (1995). Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res., 55, 4471-4478.
27. LANE, D.P. (1992). p53, guardian of the genome. Nature, 358, 15-16.
28. LEEK, R.D., KAKLAMANIS, L., PEZZELLA, F., GATTER, K.C. & HARRIS, A.L. (1994). bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor-negative tumours and in situ cancer. Br. J. Cancer, 69, 135-139.
29. 3 analogues in breast cancer cells. Cancer Res. , 56, 2789-2794.
30. MACKAY, A.G., OFORI-KURAGU, E.A., LANSDOWN, A., COOMBES, R.C., BINDERUP, L. & COLSTON, K.W. (1996). Effects of the synthetic vitamin D analogue EB1089 and tamoxifen on the growth of experimental rat mammary tumours. Endo-Rel. Cancer, 3, 327-335.
31. MANSI, J.L. & SMITH, I.E. (1989). Endocrine therapy for breast cancer: mechanisms and new approaches. J. Cancer Topics, 7, 57-59.
32. MATHIASEN, I.S., COLSTON, K.W. & BINDERUP, L. (1993). EB1089, a novel vitamin D analogue, has strong anti-proliferative effects and differentiation inducing effects on cancer cells. J. Steroid Biochem. Molec. Biol., 46, 365-371.
33. MERLO, G.R., BASOLO, F., FIORE, L., DUBOC, L. & HYNES, N.E. (1995). p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. J. Cell. Biol., 128, 1185-1196.
34. MIYASHITA, T. & REED, J.C. (1995). Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80, 293-299.
35. MOLL, U.M., RION, G. & LEVINE, A.J. (1992). Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. U.S.A., 89, 7262-7266.
36. 3-resistant MCF-7 cell line. Endocrinology, 137, 400-409.
37. OLTVAI, Z.N., MILLIMAN, C.L. & KORSMEYER, S.J. (1993). Bcl-2 heterodimerises in vivo with a conserved homologue, bax, that accelerates programmed cell death. Cell, 80, 285-291.
38. REED, J. (1994). bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124, 1-6.
39. SAKAKURA, C., SWEENEY, E.A., SHIRAHAMA, T., IGARASHI, Y., HAKOMORI, S.I., NAKATANI, H., TSUJIMOTO, H., IMANISHI, T., OHGAKI, M., OHYAMA, T., YAMAZAKI, J., HAGIWARA, A., YAMAGUCHI, T., SAWAI, K. & TAKAHASHI, T. (1996). Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int. J. Cancer, 67, 101-105.
40. SCHMITZ, G., WALTER, T., SEIBL, R. & KESSLER, C. (1991). Non-radioactive labelling of oligonucleotides in vitro with the hapten digoxigenin by tailing with terminal transferase. Analyt. Biochem., 192, 222-231.
41. SHAW, P., BOVEY, R., TARDY, S., SAHLI, R., SORDAT, B. & COSTA, J. (1992). Induction of apoptosis by wild-type p53 in a human colon tumour derived cell line. Proc. Natl. Acad. Sci. U.S.A., 89, 4495-4499.
42. 3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res. Treat., 42, 31-41.
43. 31P spectroscopy and histological studies of the response of rat mammary tumours to endocrine therapy. Br. J. Cancer, 62, 258-262.
44. VANWEELDEN, K. & WELSH, J. (1997). The vitamin D analogue EB1089 induces regression of MCF-7 xenografts in nude mice. In Vitamin D; chemistry, biology and clinical applications of the steroid hormone, ed. Norman, A.W., Bouillon, R. & Thomasset, M. pp. 417-418. University of California.
45. 3 analogue, EB1089. Endocrinology, 139, 2102-2110.
46. 3 and the vitamin D3 analogue EB1089. Eur. J. Cancer, 32A, 842-848.
47. WANG, T.T.Y. & PHANG, J.M. (1995). Effects of oestrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res., 55, 2487-2489.
48. WARRI, A.M., HOUVINEN, R.L., LAINE, A.M., MARTIKAINEN, P.M. & HARKONEN, P.L. (1993). Apoptosis in toremifene-induced growth of human breast cancer cells in vivo and in vitro. J. Natl. Cancer Inst., 85, 1412-1418.
49. WILLIAMS, G.T. (1991). Programmed cell death: apoptosis and oncogenesis. Cell, 65, 1097-1098.
50. WILLIAMS, J.C., GUSTERSON, B., HUMPHREYS, J., MONAGAN, P., COOMBES, R.C., RUDLAND, P. & NEVILLE, A.M. (1981). N-methyl-N-nitrosourea-induced rat mammary tumours. Hormone responsiveness but lack of spontaneous metastasis. J. Natl. Cancer Inst., 66, 147-155.
51. WYLLIE, A.H. (1987). Apoptosis: cell death in tissue regulation. J. Pathol., 153, 313-316.
52. XIE, S.P., JAMES, S.Y. & COLSTON, K.W. (1997). Vitamin D derivatives inhibit the mitogenic effects of IGF-1 on MCF-7 human breast cancer cells. J. Endocrinol., 154, 495-504.
53. YANG, E. & KORSMEYER, S.J. (1996). Molecular thanatopsis; a discourse on the bcl-2 family and cell death. Blood, 88, 386-401.
54. YONISH-ROUACH, E., RESNITZKY, D., LOTEM, J., SACHS, L., KIMCHI, A. & OREN, M. (1991). Wild-type p53 induces apoptosis of myeloid leukaemia cells that is inhibited by interleukin-6. Nature, 352, 345-347.
55. YU, C.-L., DRIGGERS, P., BARRERA-HERNANDEZ, NUNEZ, S.B., SEGARS, J.H. & CHENG, S.-Y. (1997). The tumour suppressor p53 is a negative regulator of oestrogen receptor signalling pathways. Biochem. Biophys. Res. Commun., 239, 617-620.